Oncologix Tech, Inc.
Other OTCTotal Valuation
Oncologix Tech, Inc. carries a market capitalization of 73,662.00, placing it among publicly traded companies globally. Its enterprise value stands at 3.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 73,662.00 |
| Enterprise Value | 3.72M |
Share Statistics
Oncologix Tech, Inc. currently has 276.75M shares outstanding.
| Shares Outstanding | 276.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.13, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 0.13 |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.17 |
| P/FCF Ratio | -1.08 |
| P/OCF Ratio | -1.07 |
Enterprise Valuation
| EV / Sales | 0.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 6.51 |
Financial Position
Oncologix Tech, Inc. maintains a current ratio of 0.28, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -271.49, indicating conservative leverage, while an interest coverage ratio of -0.50 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.28 |
| Quick Ratio | 0.25 |
| Debt / Equity | -271.49 |
| Debt / EBITDA | -5.64 |
| Interest Coverage | -0.50 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -55.92 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 43.24 |
Income Statement
Over the trailing twelve months, Oncologix Tech, Inc. generated 4.61M in revenue and converted that into -1.75M in net income, yielding earnings per share of -0.01. EBITDA reached -572,640.00, while operating income came in at -592,659.00.
| Revenue | 4.61M |
| Gross Profit | 958,918.00 |
| Operating Income | -592,659.00 |
| Pretax Income | -1.75M |
| Net Income | -1.75M |
| EBITDA | -572,640.00 |
| EBIT | -592,659.00 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Oncologix Tech, Inc. holds 120,485.00 in cash and equivalents against 3.23M in total debt, resulting in a net debt position of 3.11M. Total book value stands at -49.59M, with working capital of -3.35M providing operational flexibility.
| Cash & Cash Equivalents | 120,485.00 |
| Total Debt | 3.23M |
| Net Debt | 3.11M |
| Equity (Book Value) | -49.59M |
| Book Value Per Share | -0.27 |
| Working Capital | -3.35M |
Cash Flow
Oncologix Tech, Inc. produced -570,250.00 in operating cash flow over the past twelve months. After subtracting -2,033.00 in capital expenditures, free cash flow totaled -572,283.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -570,250.00 |
| Capital Expenditures | -2,033.00 |
| Free Cash Flow | -572,283.00 |
| FCF Per Share | 0.00 |
Margins
Oncologix Tech, Inc. operates with a gross margin of 20.82, reflecting its pricing power and cost economics. The operating margin of -12.87 and net profit margin of -37.98 provide insight into operational efficiency.
| Gross Margin | 20.82 |
| Operating Margin | -12.87 |
| Pretax Margin | -37.98 |
| Profit Margin | -37.98 |
| EBITDA Margin | -12.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -174.40 |
| FCF Yield | -92.84 |
Stock Splits
Oncologix Tech, Inc.'s most recent stock split took place on May 19, 2011 with a 4:1 split ratio.
| Last Split Date | 5/19/2011 |
| Split Ratio | 4:1 |
Scores
Oncologix Tech, Inc. posts an Altman Z-Score of -49.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -49.78 |